Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2601-2604

  Poeta, Julia ^a   Linden, Rafael ^b   Antunes, Marina Venzon ^b   Real, Lucia ^a   Menezes, Andréia Magalhães ^a   Ribeiro, Jorge P ^a,c   Sprinz, Eduardo ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEEVALE   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Aids; Antiretroviral therapy; Therapeutic drug monitoring

Indexed keywords

EFAVIRENZ;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; BRAZIL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; EVENING DOSAGE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MALE; SEX DIFFERENCE; TIME; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS LOAD;

ADULT; AGED; AGING; ANTI-HIV AGENTS; BENZOXAZINES; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 80054702221     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr360     Document Type: Article

References (10)

1. Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
2. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
3. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
4. López-Cortés LF, Ruiz-Valderas R, Marin-Niebla A et al. Therapeutic drug monitoring of efavirenz. J Acquir Immune Defic Syndr 2005; 39: 551-6.
5. Pfister M, Labbé L, Hammer SM et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003; 47: 130-7.
6. Bazzoli C, Jullien V, Le Tiec C et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 2010; 49: 17-45.
7. Antunes MV, Poeta J, Ribeiro JP et al. Ultra-performance liquid chromatographic method for simultaneous quantification of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors in human plasma. J Bras Chem Soc 2011; 22: 134-41.
8. Stöhr W, Back D, Dunn D et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13: 675-85.
9. Kappelhoff BS, Huitema AD, Yalvaç Z et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44: 849-61.
10. Kappelhoff BS, van Leth F, MacGregor TR et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145-55.